haydonat
☆    

Turkey,
2011-04-23 12:52
(5539 d 07:12 ago)

Posting: # 6937
Views: 4,065
 

 interference problem [Bioanalytics]

Dear all,

I have a big problem :(:(:(

I'm developing olanzapine method by UPLC-MS/MS with olanzapine-d3 as internal standard. I have a few runs with very good results but a lot of runs with bad results just for QC1 levels, because of big interferences.

Although interference areas are too high, they do not effect QC2 levels and 9 out of 10 different blank sources have no interference. Matrix effect analyses were performed twice with different concentrations and %CV values are 15 and 16.

In one of matrix effect analysis one set of blank sample has both olanzapine and olanzapine-d3 peaks each of 6 injections with different amounts (we expect to observe only olanzapine-d3, because internal standard stock solution was spiked in to tubes).

Also, same results were observed with different analysts and different days.

What do you suggest to us?

Thank you all,
Hale
haydonat
☆    

Turkey,
2011-04-27 01:44
(5535 d 18:19 ago)

@ haydonat
Posting: # 6944
Views: 3,251
 

 random interference

Dear all,

I have a big random interference problem :(:(

I'm developing olanzapine method by UPLC-MS/MS with olanzapine-d3 as internal standard. I have 4 runs with very good results but some runs with bad results because of big random interferences.

At the same batch, 3 different extracted same blank sample values are 450, 35000, 48.
And the results of reinjection of these blank samples values remain unchanged.

And 9 out of 10 different blank sources have no interference. Matrix effect analyses were performed and %CV value is 10.


-extraction procedure: liquid-liquid sample preparation with tert-buthyl-methyl-ether
-column: sunfire c18
-mobile phase: Acetonitrile:water:formic acid (50:50:0.1, v:v:v)
-reconstitue solution: mobile phase
-injection volume: 10 µl
-flow rate: 0.3 ml/min
-Analyzed by MS in the multiple reaction monitoring mode using the respective [M + H]+ ions, m/z 313/256 for olanzapine and m/z 316/256for the IS(olanzapine-d3).

And also, there is no interference on mobile phase and methanol injections.

Also, same results were observed with different analysts and different days.

What do you suggest to us?

Thank you all,
Hale


Edit: Post linked to similar thread. Please don't fork in the future. [Helmut]
UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
150 visitors (0 registered, 150 guests [including 33 identified bots]).
Forum time: 20:04 CEST (Europe/Vienna)

Scientists cannot simply hang their subjectivities
up on a hook outside the laboratory door.    Ruth Bleier

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5